Response to Pazopanib in Patients with Relapsed Osteosarcoma

Kunal R. Elete, Karen H. Albritton, Lauren J. Akers, Riyaz Basha, Anish Ray

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Axial skeleton primary tumor, metastatic disease at presentation, incomplete surgical resection, and <90% tumor necrosis have all been known to influence prognosis adversely in osteosarcoma. Relapse of osteosarcoma, typically occurring within the first 18 months of therapy, with an incidence rate of 50% is treated with surgery, chemotherapy, and targeted therapy. Here, we discuss 2 patients treated with pazopanib, a multi-tyrosine kinase inhibitor presently approved to treat renal cell carcinoma and soft tissue sarcomas. Case 1 achieved positive response and remains on pazopanib. Case 2 sustained gastrointestinal toxicity requiring suspension of drug, despite achieving stable disease.

Original languageEnglish
JournalJournal of Pediatric Hematology/Oncology
StateAccepted/In press - 2018


  • MAP
  • oncology
  • pazopanib
  • pediatric osteosarcoma
  • relapsed


Dive into the research topics of 'Response to Pazopanib in Patients with Relapsed Osteosarcoma'. Together they form a unique fingerprint.

Cite this